Global Access Diagnostics (GADx), a social enterprise prioritising equitable access to diagnostics, has introduced IT-Leish, a rapid diagnostic test (RDT) for visceral leishmaniasis (VL). The company acquired the manufacturing rights for IT-Leish from Bio-Rad in September 2022 to prevent its withdrawal from the market and has since ensured the regulatory requirements have been met for reintroduction to the market.
IT-Leish is a high-performance, immuno-chromatographic RDT that is used for the diagnosis of VL, a life-threatening neglected tropical disease (NTD) transmitted by phlebotomine sandflies. Early VL diagnosis is a vital component of controlling the disease, which is considered fatal if not treated rapidly. IT-Leish is a trusted RDT, taking 20 minutes to generate results. It provides reliable and accurate confirmation of clinically suspected cases of VL to enable early diagnosis, reducing disease fatality.